Vertex to buy Crinetics for $10B, adding endocrine drugs
What's the deal? Vertex PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, a total equity value of about $10 billion, or roughly $8.8 billion net of estimated cash acquired. Both boards unanimously approved the deal, which is expected to close in the third quarter of 2026.
What's the endgame? Crinetics, a San Diego-based company focused on endocrine diseases, brings a portfolio Vertex says carries a peak sales opportunity of roughly $5 billion. Its lead marketed product, PALSONIFY, won FDA approval in September 2025 as the first and only once-daily oral therapy for adults with acromegaly, a rare condition affecting an estimated 20,000 diagnosed people in the US.
What else is in the pipeline? Crinetics' most advanced candidate, atumelnant, is in Phase 3 development for congenital adrenal hyperplasia, a rare genetic disease with 17,000 addressable patients in the US in its classic form. In Phase 2 studies, patients achieved near-normalization of excess androgen levels; the drug has also shown potential in Cushing's syndrome.
Why now? The deal extends Vertex's strategy of buying capabilities in serious, specialty diseases rather than simply adding revenue. "Crinetics is an excellent strategic fit for Vertex, with its focus on serious diseases in specialty markets with significant unmet need," said chief executive officer Reshma Kewalramani.
The context: Vertex has leaned on M&A to add new therapeutic areas, buying ViaCyte for type 1 diabetes work and completing its largest deal to date in 2024 — the roughly $4.9 billion acquisition of Alpine Immune Sciences to expand into kidney disease and immunology. Crinetics itself drew investor confidence, closing an oversubscribed $350 million private placement in February 2024.
What could go wrong? The transaction is not slated to close until the third quarter of 2026, leaving room for regulatory or market shifts. Atumelnant remains in Phase 3, and PALSONIFY's commercial momentum, while early and growing, is still unproven at scale.
The signal: The acquisition positions endocrine disorders as another strategic pillar for Vertex alongside cystic fibrosis, kidney disease, and diabetes. It reflects a broader trend of large-cap biotechs paying up for late-stage, specialist assets rather than pursuing mega-pharma mergers.
Read more: The Wall Street Journal
Image credit: zhouxuan12345678
